SCHEMBL2366009

SCHEMBL2366009

Cc1cnc(N2CCN(C(=O)c3c(F)cc(N4CCOC4=O)cc3F)CC2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.38
BCR P11274 2/20 0.38
LMNA P02545 6/20 0.37
TP53 P04637 4/20 0.35
KDM4E B2RXH2 2/20 0.35
SMO Q99835 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 2/20 0.35
CYP11B2 P19099 1/20 0.35
HTT P42858 3/20 0.34
TSHR P16473 2/20 0.34
IDH1 O75874 3/20 0.34
POLB P06746 1/20 0.34
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366019 0.88 HTT (0.43) LMNATP53KDM4EALDH1A1MAPT
SCHEMBL14686756 0.85 MEN1 (0.39) ABL1BCRLMNATP53KDM4E
SCHEMBL2366052 0.84 MEN1 (0.44) LMNAKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL2366915 0.84 MEN1 (0.45) LMNAKDM4EALDH1A1MAPTHTT
SCHEMBL2369387 0.84 MAOB (0.37) ABL1BCRLMNATP53KDM4E
SCHEMBL2369381 0.84 MAOB (0.37) ABL1BCRLMNATP53KDM4E
SCHEMBL14687305 0.83 KDM4E (0.38) ABL1BCRLMNATP53KDM4E
SCHEMBL14686977 0.83 KDM4E (0.38) ABL1BCRLMNATP53KDM4E
SCHEMBL14687331 0.83 MEN1 (0.46) ABL1BCRLMNATP53KDM4E
SCHEMBL2367034 0.83 ALDH1A1 (0.41) LMNATP53KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 ABL1 4111/4885BCR 4634/4885LMNA 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.